Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials

Main Article Content

Andrew Blauvelt
George Han
Steve Tyring
Jennifer Soung
Tae Oh
Leah Davis
Veerle Vanoorden
Mark Lebwohl

Keywords

bimekizumab, psoriasis, efficacy, phase 3 trial

Abstract

N/A

References

1.Glatt S et al. Br J Clin Pharmacol 2017;83:991–1001;

2. Papp KA et al. J Am Acad Dermatol 2018;79:277–286.e10;

3. Gordon KB et al. Lancet 2021;397:475–86;

4. Reich K et al. Lancet 2021;397:487–498;

5. Warren R et al. N Engl J Med 2021;385(2):130–141;

6. Reich K et al. N Eng J Med 2021; DOI: 10.1056/NEJMoa2102383. A

Most read articles by the same author(s)

<< < 4 5 6 7 8 9 10 > >>